

Daily evidence digest

17 May 2022

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Prone positioning and endotracheal intubation, impact of leadership on the nursing workforce, prevalence of post-intensive care syndrome

Peer reviewed journals featured:

- A randomised clinical trial of awake prone positioning on endotracheal intubation in patients with COVID-19 and acute respiratory failure [here](#)
- Observational studies on:
 - Impact of leadership on the nursing workforce during COVID-19 [here](#)
 - Prevalence of post-intensive care syndrome in mechanically ventilated COVID-19 patients [here](#)
 - Association of prior Comirnaty (Pfizer) vaccination with symptomatic SARS-CoV-2 infection in children and adolescents during Omicron predominance [here](#)
 - Venous or arterial thrombosis and deaths among COVID-19 cases in Europe [here](#)
 - Post-COVID-19 conditions in COVID-19 children and adolescents in Germany [here](#)
 - Sex differences in global metabolomic profiles of COVID-19 patients [here](#)
 - Physiologic profile associated with severe multisystem inflammatory syndrome in children [here](#)
 - An intradermal Vaxzevria (AstraZeneca) boost in a healthy population [here](#)
 - Immunity against Omicron following heterologous immunisation with inactivated vaccine followed by mRNA-booster [here](#)
- Commentary on:
 - Lessons for Australia re COVID-19 and chronic disease management in primary care [here](#)
 - Calling time on the use of war metaphors in COVID-19 [here](#)

Letters and correspondence discussed:

- Clinical care of children and adolescents with COVID-19 [here](#)
- Risk of infection and hospitalisation in vaccinated and unvaccinated children and adolescents in New York after the emergence of the Omicron variant [here](#)
- Neutralising antibodies against Omicron (BA.1), 1 - 18 weeks after second and third doses of Comirnaty (Pfizer) vaccine [here](#)

Guidance and reports

- The Therapeutic Goods Administration (TGA) has commenced evaluation of Moderna COVID 19 vaccine (SPIKEVAX) for children aged 6 months to 5 years old [here](#)

News and blogs

- WHO chief calls for a shift in China's "unsustainable" policy [here](#)

[Click here](#) to subscribe to the daily evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on SARS-CoV-2 [vaccines](#), and [variants](#) of concern, [post-acute sequelae of COVID-19 \(PASC\)](#), [surgery and COVID-19](#), [rapid testing](#) and [risk mitigation strategies](#).